Texas
LATEST FROM BIOSPACE
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.
Here’s a look at a few of the industry expansions that have been announced so far this month.
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
During the past two years, fundraising and investment in biotechnology have reached record levels.
The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.
There were a fair number of clinical trial announcements last week. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
PRESS RELEASES